News

The company said that the top-line results demonstrated high clinical cure rates of over 90% following the step-down therapy with oral iclaprim administered after two days of initial

Under the terms of the agreement, Novocell will receive an upfront payment with additional amounts payable upon the achievement of certain technical milestones, as well as research funding.

The compulsory acquisition followed an offer dated October 3, 2008 for all of the CryoCath shares at a price of C$8.75 per CryoCath share, which had been accepted

CorVue is a cardiac pharmacologic stress SPECT (single-photon-emission computed tomographic) imaging agent intended for use in patients with or at risk for coronary artery disease (CAD) who are

Additionally, former chairman of Respironics, Gerald McGinnis, has committed to provide up to $1.8 million in the form of convertible debt for bridge funding, to allow the company

SurgiLance safety lancets are also used in point-of-care diagnostic testing, including diabetes testing and testing for HIV, said MediPurpose. Smiths Medical was recently named as exclusive distributor for

The management team plans to deploy the capital from this first closing for initial product acquisitions that are already well advanced in the negotiation and due diligence process,

The offer will now expire on January 9, 2009, unless further extended or earlier terminated. The tender offer was extended to comply with a continuing order issued by

The tender offer was originally scheduled to expire on December 23, 2008. All other terms and conditions of the tender offer remain unchanged. As previously disclosed, the conditions